HONG KONG and MANILA, PHILIPPINES and PHILADELPHIA, PA--(MARKET WIRE)--May 28, 2008 -- VERSA CARD, INC. (OTC BB:IGLB.OB - News) (formerly Intrepid Global Imaging 3D, Inc.) ("VERSA") today reported that it has signed a Letter of Intent ("LOI") with the MacKay Group Limited (MKG) to appoint VERSA as the exclusive provider of smartcard technology and related services to MKG's recently announced planned Joint Venture in China.

The MacKay Group Limited (MKG) recently announced on Friday May 23, 2008, that it has signed a memorandum of understanding (MOU) with the appointed agent of Jiashen Lifecare Investment Management Company Limited (CareLife), China International Medical Exchange Ltd (CIME), to form a joint venture in China with CareLife, anticipated to close in June 2008.

Clients of the JV will include the two largest insurance companies in China along with a top China bank. Management believes that this LOI will open a window of opportunity to introduce VERSA to leading insurance companies, state-owned banks, CareLife's Medical Clinic Centers and government hospitals across China.

MKG further stated that, it was at the request of its partners and potential clients, that MKG was asked to bundle in VERSA's technology, plus another technology as part of this process. The second technology was True Product ID, Inc. ("TPID"). MKG has appointed True Product ID, Inc. as the exclusive provider for the anti-counterfeiting solutions for the Carelife joint venture, and TPDI has accepted the appointment and agrees to provide such anti-counterfeiting solutions.

Currently, MKG holds a Master License Agreement from Biofield Corp. for the exclusive distribution, development, manufacturing, clinical, regulatory, and R&D rights worldwide with regard to the Biofield Breast Cancer Technology. Biofield's breast cancer diagnostic device, the Biofield Diagnostic System (BDS), employs single-use sensors designed by Biofield and a measurement device to detect and analyze changes associated with the development of epithelial cancers, such as breast cancer.

Given China's challenges with counterfeit or substandard medical technology, Carelife has also asked MKG to protect each of the BDS devices, 18 single-use sensors needed for each BDS test, and VERSA's smartcards used to pay for each BDS test with TPID's leading anti-counterfeiting technology.

CareLife is a Medical Clinic Centre which sells their business through memberships. It is anticipated that it could be made mandatory that all members need to at least get one BDS test per year as part of their application renewal. Further, the same may be required by the insurance company partners to require their policyholders to go through a yearly medical check-up in order to renew and /or become eligible for their insurance policy coverage. The banking partners may also offer this service to its clients. The tests can be paid utilizing VERSA's smartcards. These smartcards can also track and maintain records on individual usage, medical history and other related financial and identity matters.

About VERSA CARD INC.:

Versacard (First Versatile Smartcard Solutions Corporation) A Smartcard Company within the MacKay Group Portfolio of companies, is a multiple application electronic purse on a smart card. It is an electronic payment system using a pre-paid contactless cash card that can be used to pay for purchases/transactions in transport systems, convenience stores, fast-food outlets, gas stations, drugstores, supermarkets, ATMs, cell phones, vending machines, toll roads, parking, and other commercial establishments as well as pay bills.

Versacard is strategically placed to be the leader in the "Smartcard/ Cashless Revolution" and the leading provider of integrated smartcard technology in Asia. Versacard has established strategic alliances with prominent government, industry, and banking leaders, in the Philippines, India and China and the surrounding regions. For more information go to: www.versacard.net and http://themackaygroup.net/versacard.htm.

About MacKay Group Limited:

MacKay Group Limited is a private corporation that pursues diverse and significant opportunities around the globe. It has a portfolio of investments in a variety of companies, ventures, and projects including those associated with advanced technology, healthcare, the financial sectors, sports, mining, port development, oil/gas, among others. MKG has gained the respect of government and industry leaders around the world. For more information go to: www.themackaygroup.net.

About Biofield:

Biofield Corp. is a development-stage medical technology company that has developed a device to assist in detecting breast cancer in a non-invasive procedure. The Company's breast cancer diagnostic device, the Biofield Diagnostic System (BDS), employs single-use sensors designed by Biofield and a measurement device to detect and analyze changes associated with the development of epithelial cancers, such as breast cancer. The Biofield Diagnostic System takes multiple readings from an array of test points on the skin surface of the symptomatic breast and asymptomatic breast to measure differentials that may exist between test points. For more information go to: www.biofield.com.

SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that our products may not achieve customer acceptance or perform as intended, that we may be unable to obtain necessary financing to continue operations and development, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Contact:

Contact:
Zacarias Rivera
Email Contact